ILNS News 0.0064 04/30/2014 05:40:09 Intellect Neuroscien (I

New Post Public Reply Private Reply Replies (0) Message Board

Apr 30, 2014 at 6:39 AM

Intellect Neuroscien (ILNS) 0.0064 $ILNS

Intellect Neurosciences, Inc. Announces Positive Top Line Data Showing Proof of Concept in a Preclinical Alzheimer's Model for Its TauC3 Monoclonal Antibody Indicating its Potential to be Disease Modifying
GlobeNewswire - Thu Jan 16, 2:19AM CST
via PRWEB - Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic and diagnostic agents for the treatment of Alzheimer's and other neurological diseases, today announced it obtained proof of concept in a preclinical Alzheimer's model for its TauC3 monoclonal antibody indicating its potential to be disease modifying. The study was conducted in collaboration with University of California, Irvine's Dr. Frank LaFerla, Chancellor's Professor and Chair, Neurobiology and Behavior School of Biological Sciences, Director, Institute for Memory Impairments and Neurological Disorders as well as Dr. Kim Green and his team. The data showed that the TauC3 antibody effectively engaged the target and reduced certain phosphorylated pathological forms of Tau indicating that the treatment with the peripherally administered antibody had an effect in the brain and is able to be disease modifying. The investigators aim to publish the full data in a peer-reviewed scientific journal.

Intellect Neurosciences Obtains Patent Allowance From the United States Patent and Trademark Office in Relation to Its TOC-1 Monoclonal Antibody Selective for Pre-Fibrillar Tau Aggregates
GlobeNewswire - Thu Nov 14, 1:15PM CST
Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic and diagnostic agents for the treatment of Alzheimer's and other neurological diseases, today announced it obtained a Notice of Allowance from the United States Patent and Trademark Office (USPTO). The patent allowance is in relation to TOC-1, a monoclonal antibody that selectively binds neurotoxic pre-fibrillar tau aggregates which are important pathological components in Alzheimer's disease (AD) and other neurodegenerative tauopathies. Intellect previously obtained development and commercialization rights to TOC-1 under an exclusive license agreement with Northwestern University.

OTC Daily Alert Stock Watch - Intellect Neurosciences, Inc. (OTCQB:ILNS)
WorldStockWire - Tue Aug 13, 6:45PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com

Intellect Neurosciences Retains Chain Pharmaceuticals LLC
GlobeNewswire - Tue Jul 30, 10:30AM CDT
Intellect Neurosciences, Inc. (OTCBB:ILNS) announced today it has retained Chain Pharmaceuticals LLC as a consultant to assist the company in managing its patent estate and external collaborations and pursuing strategic alternatives for the company, which may include partnerships, strategic business model alternatives, a sale or other transaction.

Intellect Neurosciences, Inc. Issues Letter to Shareholders
GlobeNewswire - Thu Jun 20, 8:25AM CDT
Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company engaged in the discovery and development of treatments for the prevention and treatment of neurodegenerative diseases, issued the following Letter to Shareholders from Elliot Maza, a member of the Board of Directors of the company.

NY biotech financier gets prison for stock scheme
By LARRY NEUMEISTER - AP - Thu May 02, 7:35PM CDT
NEW YORK (AP) — A federal judge displayed anger as she handed down a four-year prison sentence Thursday to a biotechnology financier who was once among the nation's wealthiest people.

Intellect Neurosciences Issues Letter to Shareholders
GlobeNewswire - Fri Mar 29, 8:35AM CDT
Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company engaged in the discovery and development of treatments for the prevention and treatment of neurodegenerative diseases, issued the following Letter to Shareholders from Dr. Daniel Chain, Chairman and CEO.

Intellect Neurosciences to Present at Bio-Europe Spring Conference in Barcelona
GlobeNewswire - Thu Feb 28, 8:35AM CST
Intellect Neurosciences, Inc. (OTCBB:ILNS) announces Dr. Daniel G. Chain, Chairman and CEO, will present at the Bio-Europe Spring Conference March 11-13, 2012 at the Centre Convencions Internacional in Barcelona, Spain.

Market Maker Surveillance Report. DVAX, FCX, PSSI, CIM, S, ILNS, Highest Net Sell Volume and Negative Price Friction For Tuesday, February 19th 2013
M2 - Wed Feb 20, 2:23AM CST
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Tuesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Tuesday there were 3840 companies with "abnormal" market making, 3574 companies with positive Friction Factors and 2220 companies with negative Friction Factors. Here is a list of the top companies with the highest net sell volume on Tuesday and lowest negative price Friction (bearish). This means that there was more selling than buying in the stocks and their stock prices dropped faster with less Friction. Dynavax Technologies Corp (NASDAQ

VAX), Freeport-McMoRan Copper & Gold Inc (NYSE:FCX), PSS World Medical Inc (NASDAQ

SSI), Chimera Investment Corp (NYSE:CIM), Sprint Nextel Corp (NYSE:S), INTELLECT NEUROSCIENCES INC (OTC:ILNS). To access Friction Factor, Naked

Intellect Neurosciences Initiates in vivo Proof of Concept Studies in a Preclinical Alzheimer's Model for Its TauC3 Monoclonal Antibody
GlobeNewswire - Thu Feb 07, 8:35AM CST
Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment of Alzheimer's and other neurological diseases, today announced it has initiated in vivo proof of concept studies for its monoclonal antibody, TauC3, in a preclinical model of Alzheimer's disease. The studies are being conducted in collaboration with University of California, Irvine's Dr. Frank LaFerla, Chancellor's Professor and Chair, Neurobiology and Behavior School of Biological Sciences, Director, Institute for Memory Impairments and Neurological Disorders as well as Dr. Kim Green and his team.

Novel Alzheimer's Therapeutics Developer Says Investors Should Remain Undeterred Despite Disappointing Results From Major Phase 3 Trials
Marketwire - Wed Jan 30, 7:08AM CST
During his distinguished career, Dr. Daniel G. Chain, Ph.D. discovered various novel therapeutics to treat Alzheimer's disease which were licensed to multiple Big Pharma giants.

Intellect Neurosciences CEO Daniel Chain Provides Conference Highlights of Alzheimer's Drug Development Summit in Neurotech Insights Magazine
GlobeNewswire - Wed Jan 02, 8:35AM CST
Intellect Neurosciences, Inc. (OTCBB:ILNS) announces Dr. Daniel G. Chain, Chairman and CEO, provided conference highlights from the December 11-12 Alzheimer's Drug Development Summit in Neurotech Insights magazine. Dr. Chain was a Distinguished Speaker at the conference.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

CAE Boosts Fiscal 2027 Outlook; Transformation On Track

Revenue's down by a hair, but it's not as bleak as it seems. CAE Inc. (NASDAQ:CAE) just put its cards on the table for Q2 of fiscal 2027, and there's a mixed bag for us investors to chew over. Revenue dipped 2.6% year-over-year to $1,204.7 million. But hey, their adjusted EPS has climbed up to $0.33, a step up from $0.28 last year, which is a good sign of something right...

Ingram Micro Joins S&P SmallCap 600 Amid M&A Moves

Market Shufflin’ as Ingram Micro Steps In The constant ebb and flow of the stock market got right interesting with Ingram Micro Holding Corp. (NYSE: INGM) slated to crawl into the S&P SmallCap 600. This dance change-up is all thanks to Viatris Inc. (NASD: VTRS) looking to wrap up its acquisition of Pacira BioSciences (NASD: PCRX). With this deal sealing the fate of...

'Luz de las Naciones' Event: A Cultural Milestone

A Vibrant Showcase of Culture and Faith Grab your seatbelt, because when you hear about a cultural event lighting up the scene, especially one backed by The Church of Jesus Christ of Latter-day Saints, it means something's brewing. We're diving headfirst into 'Luz de las Naciones,' a celebration that's keeping its promise to highlight Latin America's zest and vibrant...

Elron Ventures Advances Dual-Use Tech Investment Plans

A Strategic Dance through Conferences Elron Ventures is gearing up for an action-packed November slate, aiming to flaunt its prowess in investment across burgeoning tech fields like Defense Tech, Deep Tech, Cybersecurity, and AI. Now, any seasoned investor knows these are the buzzy sectors that could just be the workhorses pulling the future market cart. But what makes...

GFL's Big Share Conversion: Impact and Implications

Unpacking GFL Environmental's Share Conversion Here's a doozy straight from the gritty world of finance: GFL Environmental Inc. (NYSE: GFL) has announced a hefty conversion of Series A Preferred Shares into a whopping 6,219,896 subordinate voting shares. That's right, those Series A Preferred Shares, helmed by HPS Investment Partners, LLC, are now converted and sold in a...

China's Double 11 Fest Rings in $264B in 2026

Shifting Gears at the 2026 Double 11 Festival You blinked, and another record was shattered. China's "Double 11" Shopping Festival, with its rhythmic frenzy and relentless countdowns, clocked a staggering RMB 1,776.4 billion this year—roughly US$264.4 billion. This ain't no ordinary sale, it's a financial juggernaut, folks. As these platforms duke it out for every yuan,...

DarioHealth Eyes Growth with Rising Revenue and Reduced Costs

Quarterly Earnings Reflect Strategic Forward Movement This quarter, DarioHealth (NASDAQ: DRIO) decided to crank up the volume on its long-haul strategy. They've managed a respectable 6% revenue increase over last year, clocking in at $5.3 million for the third quarter of 2026. It's a slight nudge up from the previous quarter too, where they sat at $5.2 million. Not...

Can BWIN, CCC, PCRX Deals Really Serve Shareholders?

Shareholder Stakes: Caught in Controversy Well, here we go again. These days, it seems like shareholder lawsuits are cropping up as regularly as sunrise. We've got Halper Sadeh LLC on a warpath, targeting potential legal missteps in the megadeals involving Baldwin Group (NASDAQ:BWIN), CCC Intelligent Solutions Holdings (NASDAQ:CCC), and Pacira BioSciences (NASDAQ:PCRX)....

Eli Radiopharma Clinches Big Series A, Eyes Milestones

Making Waves in Radiopharmaceuticals Some days, it's not just about the numbers—it’s about the shift in an entire field. Eli Radiopharma just closed a grand RMB 400 million Series A financing, paving a path that could redefine radiopharmaceuticals. Kinfolk over at Huagai Capital led the charge, teaming up with Bayland Capital and a throng of other backers. They’re...

BSR REIT's Q3 2026 Financials: Strategic Progress Made

BSR REIT Hits Strategic Milestones in Q3 Here's a bit of exciting news hitting us from BSR Real Estate Investment Trust. They've dropped their financial results for the third quarter of 2026. Packed with some solid gains, this quarter wasn't just about the numbers—it was about the moves they've been making underneath it all. So, let's break down what they're up to, and...